Japanese MHLW approves Opdivo (nivolumab) for treatment of recurrent gastric cancer
Bristol-Myers Squibb announced the Japanese MHLW has approved Opdivo (nivolumab) for treatment of unresectable advanced or recurrent gastric cancer which has progressed after chemotherapy. This approval was based on the Phase 3 study ATTRACTION-2. September 22, 2017